ZIOP ZIOPHARM Oncology Inc

4.37
-0.06  -1%
Previous Close 4.42
Open 4.29
Price To Book 7.4
Market Cap 790,196,037
Shares 181,030,020
Volume 582,262
Short Ratio
Av. Daily Volume 1,759,325
Stock charts supplied by TradingView

NewsSee all news

  1. Ziopharm Oncology Presentation at the 38th Annual J.P. Morgan Healthcare Conference to be Webcast

    BOSTON, Dec. 19, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (NASDAQ:ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm, is scheduled to make a webcast presentation at

  2. Ziopharm Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    BOSTON, Dec. 09, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. ("Ziopharm" or the "Company") (NASDAQ:ZIOP) today reported that the Company granted a new employee an option to purchase an aggregate of 65,000 shares

  3. Ziopharm Oncology Presents Pre-Clinical Data Validating "Rapid Personalized Manufacture" (RPM) with TCR at the 2019 American Society for Hematology Annual Meeting

    – Membrane bound IL-15 (mbIL15) improves anti-tumor effect of TCR-modified T cells – – T cells expressing T-cell receptor (TCR) and mbIL15 can be infused day after gene transfer – BOSTON, Dec. 08, 2019 (GLOBE

  4. Ziopharm Oncology Presents Encouraging Clinical Data for Controlled IL-12 for the Treatment of Recurrent Glioblastoma at the 2019 Society for Neuro-Oncology Annual Meeting

    – Controlled IL-12 evaluated as monotherapy in an expanded number of patients reinforced favorable safety profile and initial data consistent with immune-mediated anti-tumor effects – – Controlled IL-12 can be combined

  5. Ziopharm Oncology Updates Presentation and Webcast Time at the Jefferies 2019 London Healthcare Conference

    BOSTON, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (NASDAQ:ZIOP) today announced that the Company's presentation at the Jefferies 2019 London Healthcare Conference on November 20, 2019, has been moved to

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 pivotal trial plans on hold due to Chemistry and Manufacturing Control (CMC) issues.
Ad-RTS-hIL-12 + veledimex
Glioblastoma multiforme (GBM)
Phase 1 completion of enrolment of third cohort announced June 26, 2019.
Ad-RTS-hIL-12 plus veledimex in combination with OPDIVO (nivolumab)
Refractory glioblastoma multiforme (GBM)
Phase 1 trial to begin later in 2019.
Sleeping beauty - TCR-T cell therapy
Solid tumors
Phase 1 data at ASCO June 2019.
Ad-RTS-hIL-12
recurrent glioblastoma (rGBM)
Phase 2 initiation announced June 27, 2019.
Ad-RTS-hIL-12 plus veledimex plus Libtayo
Refractory glioblastoma multiforme (GBM)

Latest News

  1. Ziopharm Oncology Presentation at the 38th Annual J.P. Morgan Healthcare Conference to be Webcast

    BOSTON, Dec. 19, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (NASDAQ:ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm, is scheduled to make a webcast presentation at

  2. Ziopharm Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    BOSTON, Dec. 09, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. ("Ziopharm" or the "Company") (NASDAQ:ZIOP) today reported that the Company granted a new employee an option to purchase an aggregate of 65,000 shares

  3. Ziopharm Oncology Presents Pre-Clinical Data Validating "Rapid Personalized Manufacture" (RPM) with TCR at the 2019 American Society for Hematology Annual Meeting

    – Membrane bound IL-15 (mbIL15) improves anti-tumor effect of TCR-modified T cells – – T cells expressing T-cell receptor (TCR) and mbIL15 can be infused day after gene transfer – BOSTON, Dec. 08, 2019 (GLOBE

  4. Ziopharm Oncology Presents Encouraging Clinical Data for Controlled IL-12 for the Treatment of Recurrent Glioblastoma at the 2019 Society for Neuro-Oncology Annual Meeting

    – Controlled IL-12 evaluated as monotherapy in an expanded number of patients reinforced favorable safety profile and initial data consistent with immune-mediated anti-tumor effects – – Controlled IL-12 can be combined

  5. Ziopharm Oncology Updates Presentation and Webcast Time at the Jefferies 2019 London Healthcare Conference

    BOSTON, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (NASDAQ:ZIOP) today announced that the Company's presentation at the Jefferies 2019 London Healthcare Conference on November 20, 2019, has been moved to

  6. Ziopharm Oncology Presentation at the Jefferies 2019 London Healthcare Conference to be Webcast

    BOSTON, Nov. 11, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (NASDAQ:ZIOP) today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm, is scheduled to make a webcast presentation at the

  7. Ziopharm Oncology Reports Third Quarter 2019 Financial Results

    – Phase 2 trial of Sleeping Beauty TCR-T cell therapy for patients with solid tumors initiated at the National Cancer Institute (NCI) – – New agreement with MD Anderson Cancer Center to expand library of

  8. Ziopharm Oncology to Host Conference Call to Discuss Third Quarter 2019 Results on November 7, 2019

    BOSTON, Oct. 30, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (NASDAQ:ZIOP) today announced that management will host a conference call and webcast on Thursday, November 7, at 4:30 p.m. ET to provide a corporate

  9. Ziopharm Oncology Names Drug Development Leader Dr. Chris Bowden to Board of Directors

    – Industry veteran with 20+ years of global oncology drug development leadership –   – Current CMO at Agios Pharmaceuticals; Former VP of Product Development, Oncology at Genentech –   BOSTON, Oct. 15, 2019

  10. Ziopharm Oncology Announces FDA Clearance of IND for Rapid Personalized Manufacture of CD19-specific CAR-T

    – Phase 1 clinical trial of CAR-T produced and infused in two days or less from gene transfer using Ziopharm's Sleeping Beauty platform –   – Rapid personalized manufacture of CD19-specific CAR-T for investigation in

  11. Ziopharm Oncology to Participate in the Morgan Stanley 17th Annual Global Healthcare Conference

    BOSTON, Aug. 28, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (NASDAQ:ZIOP) today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm, will participate in a webcast fireside chat at the

  12. Ziopharm Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    BOSTON, Aug. 23, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. ("Ziopharm" or the "Company") (NASDAQ:ZIOP) today reported that the Company granted a new employee an option to purchase an aggregate of 65,000 shares